Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration

Authors

  • Abdullah Ozkaya Beyoglu Eye Training and Research Hospital, Bereketzade Camii Sok, 34421, Kuledibi, Beyoglu, Istanbul.
  • Zeynep Alkin Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Irfan Perente Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Kemal Yuksel Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Okkes Baz Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Cengiz Alagoz Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Ahmet Taylan Yazici Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul
  • Ahmet Demirok Beyoglu Eye Training and Research Hospital, and Medeniyet University, Department of Ophthalmology, Istanbul

DOI:

https://doi.org/10.3126/nepjoph.v6i2.11706

Keywords:

angiogenesis, bevacizumab, cataract, lens, macular degeneration, VEGF

Abstract

Introduction: Before the era of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment, only prevention for visual loss might have been achieved in a limited number of neovascular age-related macular generation (nAMD) patients with different treatment options.

Objective: To compare the efficacy of intravitreal bevacizumab (IVB) for the treatment of nAMD between phakic and pseudophakic eyes.

Materials and methods: The newly diagnosed nAMD patients were included in this retrospective study. The patients were divided into the phakic and pseudophakic groups. Initially, the patients received three consecutive, monthly, IVB injections, and then the treatment was continued on an as-needed regimen. The patients were examined monthly, and the data at the baseline, at 3, 6, 9, and 12 months and at the last follow-up were evaluated. The changes in the visual acuity (VA), central retinal thickness (CRT) and the number of injections were compared between the two groups.

Results: The study included 62 eyes of 62 patients (39 phakic, and 23 pseudophakic patients). The mean follow-up time was 19.7 and 17.2 months in the phakic and pseudophakic groups, respectively (p = 0.06). The mean Log MAR VA at the baseline, 12 months and the last follow-up was 0.82, 0.72 and 0.75 in the phakic group and 0.77, 0.67, and 0.68 in the pseudophakic group, respectively. The change in the mean BCVA from the baseline to 12 months and at the last follow-up was not statistically different between the two groups (p = 0.9 and p = 0.7, respectively). The mean injection number at 12 months was 4.5 and 4.9 in the phakic and pseudophakic group, respectively (p = 0.2).

Conclusion: The beneficial effect of IVB is equal in both the phakic and pseudophakic group of nAMD patients. The functional and anatomical outcomes of the treatment and the number of injections were similar in the two groups.

DOI: http://dx.doi.org/10.3126/nepjoph.v6i2.11706

Nepal J Ophthalmol 2014; 6(12): 145-152

Downloads

Download data is not yet available.
Abstract
917
PDF
546

Author Biography

Abdullah Ozkaya, Beyoglu Eye Training and Research Hospital, Bereketzade Camii Sok, 34421, Kuledibi, Beyoglu, Istanbul.

MD

Downloads

Published

2014-12-12

How to Cite

Ozkaya, A., Alkin, Z., Perente, I., Yuksel, K., Baz, O., Alagoz, C., Yazici, A. T., & Demirok, A. (2014). Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration. Nepalese Journal of Ophthalmology, 6(2), 145–152. https://doi.org/10.3126/nepjoph.v6i2.11706

Issue

Vol. 6 No. 2 (2014)

Section

Original Articles

License

This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.